Pharmaceuticals Stocks

Biogen Idec Inc. Quarterly Valuation – January 2015 $BIIB


Biogen Idec should satisfy the Enterprising Investor, but not the Defensive Investor. The Defensive Investor is concerned with the lack of dividends along with the high PEmg and PB ratios, while the Enterprising Investor’s only concern is the lack of dividends. Therefore, Enterprising Investors should feel very comfortable proceeding to the next part of the analysis, which is a determination of the company’s intrinsic value.

From a valuation side of things, the company has grown its EPSmg (normalized earnings) from $3.04 in 2010 to an estimated $8.66 for 2014. This is a very strong and impressive level of demonstrated growth, which is in line with the market’s implied estimate for earnings growth of 15.08% over the next 7-10 years. In fact, actual historical growth is about 36.87% per year, so the market has priced in a significant earnings drop to a more sustainable level over the long term. The ModernGraham valuation model, therefore, returns an estimate of intrinsic value falling within a margin of safety relative to the current price, indicating the company is fairly valued at the present time.

Be sure to check out previous ModernGraham valuations of Biogen Idec Inc. (BIIB) for greater perspective!

Read the full valuation on Seeking Alpha!

BIIB Chart

BIIB data by YCharts

Disclaimer:  The author did not hold a position in Biogen Idec Inc. (BIIB) at the time of publication and had no intention of changing that position within the next 72 hours.  Logo taken from Wikipedia for the sole purpose of identifying the company; this article is not affiliated with the company in any manner.

Leave a Reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Back To Top